New hope for hard-to-treat prostate cancer: targeted radiation therapy tested
NCT ID NCT04506567
First seen Feb 21, 2026 · Last updated May 24, 2026 · Updated 12 times
Summary
This study tests a drug called 225Ac-J591 that delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if it can lower PSA levels, a marker of cancer activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brooklyn Methodist Hospital - New York Presbyterian
Brooklyn, New York, 11215, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.